Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Durvalumab + Lurbinectedin for Small Cell Lung Cancer
Recruiting2 awardsPhase 2
Rochester, Minnesota
This trial studies the effects of two drugs, durvalumab and lurbinectedin, on patients with advanced small cell lung cancer that has returned or not responded to previous treatments. Durvalumab boosts the immune system to fight cancer, and lurbinectedin stops cancer cells from growing. The goal is to see if this combination can help patients live longer without their cancer getting worse.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service